rs11052552 — CLECL1

CLECL1 rs11052552 — A Dendritic Cell Gatekeeper Variant in Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas. Genetic predisposition accounts for roughly 50% of T1D liability, and while the HLA region contributes the largest share, dozens of non-HLA loci fine-tune immune tolerance in ways that collectively tip the balance toward or away from autoimmunity. rs11052552 sits within CLECL1¹¹ CLECL1
C-type lectin-like 1, also known as DCAL-1 (dendritic cell-associated lectin-1); gene ID 160365 on chromosome 12p13.31, a gene whose protein product acts as a costimulatory molecule on dendritic cells and B cells — the very antigen-presenting cells that calibrate whether T cells attack self-tissue or stand down.

The Mechanism

CLECL1 encodes a type II transmembrane C-type lectin-like protein expressed at high levels in lymphoid tissues — particularly lymph nodes and spleen — and on circulating dendritic cells and B cells. Functionally, CLECL1 skews CD4+ T cells toward a Th2 immune profile²² skews CD4+ T cells toward a Th2 immune profile
Th2 (T-helper 2) responses favour antibody production and dampen the Th1/Th17 cytotoxic immunity associated with beta-cell destruction; the balance between Th1 and Th2 signalling is a key checkpoint in autoimmune disease by enhancing interleukin-4 production and positively regulating T-cell proliferation. Dendritic cell ligation of CLECL1 triggers downstream JNK and MAP kinase signalling, leading to partial dendritic cell maturation.

The rs11052552 G allele sits in an intronic region of CLECL1 and likely influences gene expression rather than protein structure directly. Wallace et al. (2012)³³ Wallace et al. (2012)
Wallace C et al. Statistical colocalization of monocyte gene expression and genetic risk variants for type 1 diabetes. Hum Mol Genet, 2012 used formal statistical colocalization testing to show that expression quantitative trait loci (eQTLs) in the CLECL1 region overlap with T1D GWAS risk signals in monocyte expression data from 1,370 individuals. This colocalization approach is more rigorous than simple co-location of signals, formally testing whether a shared causal variant underlies both the expression change and the disease association.

The Evidence

The primary genetic association was established in the Wellcome Trust Case Control Consortium (WTCCC) landmark 2007 GWAS⁴⁴ Wellcome Trust Case Control Consortium (WTCCC) landmark 2007 GWAS
WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, the largest GWAS of its era (14,000 cases across seven common diseases, 3,000 shared controls). In the type 1 diabetes arm, rs11052552 G allele carriers showed elevated risk with an odds ratio of approximately 1.49 in heterozygotes and 1.43 in homozygotes compared to TT homozygotes. The near-equivalent risk in TG and GG genotypes is consistent with a dominant or near-dominant mode of action — one G allele is sufficient to confer most of the excess risk, a pattern seen in other immune regulatory variants where heterozygous disruption of a costimulatory threshold is sufficient to shift immune balance.

Murphy et al. (2010)⁵⁵ Murphy et al. (2010)
Murphy A et al. Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4+ lymphocytes. Hum Mol Genet, 2010 mapped disease-associated expression polymorphisms genome-wide in CD4+ lymphocytes, providing functional context for T1D-associated regulatory variants in the chromosome 12p13 region. The chromosome 12p13 locus containing CLECL1 and neighbouring immune genes (CD69, KLRF1) is a cluster of C-type lectin-like genes with coordinated expression in antigen-presenting cells, suggesting the T1D risk signal may reflect broader regulatory effects across this immune gene cluster.

Population stratification in this variant is notable: the G allele ranges from 21% in African-ancestry populations to 63% in East Asian populations. This means the baseline risk conferred by the G allele is more common in European (51%) and East Asian (63%) populations where most T1D epidemiology has been conducted, and considerably rarer in African populations.

Practical Actions

Type 1 diabetes is an autoimmune condition, not the lifestyle-driven type 2 diabetes. Carrying the G allele does not cause T1D — it modestly shifts immune regulatory balance in ways that increase susceptibility when combined with other genetic and environmental factors (viral triggers, early-life microbiome, vitamin D status). The absolute risk remains low: T1D affects approximately 0.4% of the global population, and carrying one or two G alleles at this single locus shifts that baseline by a fraction commensurate with the OR of ~1.4–1.5.

Actionable monitoring focuses on early detection — catching T1D at its autoimmune stage (positive autoantibodies) before clinical hyperglycaemia develops, when interventions have the greatest potential benefit. Vitamin D sufficiency has consistent epidemiological associations with reduced T1D incidence and may support immune regulation relevant to CLECL1-mediated Th2/Th1 balance.

Interactions

rs11052552 lies within a cluster of C-type lectin-like immune genes on 12p13 (CLECL1, CD69, KLRF1, CLEC2D). CD69 is separately listed as a T1D candidate gene in the same 2009 meta-analysis (PMID 19430480). Individuals carrying risk alleles at multiple loci in this immune-regulatory region may have compounding effects on T-cell costimulatory thresholds. The CLECL1 signal also likely interacts with HLA class II alleles (the primary genetic T1D determinant) in ways that haven't been fully characterised — HLA-DR/DQ genotype and non-HLA modifiers such as this variant are thought to act semi-independently on distinct steps of immune tolerance.